Turn the Tide Act
- Sponsor
- Rep. Pappas, Chris [D-NH-1]
- Committees
- Oversight and Government Reform Committee (primary)
- Last action
- Jul 16, 2026
Bottom line
The Turn the Tide Act proposes a substantial, multi-year federal investment and significant policy changes to intensify the national response to the opioid crisis and broader substance use disorders.
What it actually does
This bill reauthorizes and significantly increases funding for a wide array of federal programs designed to combat the opioid crisis and address substance use disorders, primarily those established or amended by the SUPPORT for Patients and Communities Act. It also introduces new federal mandates for Medicaid and private health insurance regarding coverage and cost-sharing for medication-assisted treatment (MAT) and opioid overdose reversal agents, and establishes new grant programs for law enforcement mental health and adverse childhood experiences response teams. The bill aims to bolster prevention, treatment, and recovery services nationwide.
Proponents argue
Proponents argue that this bill is a critical and comprehensive response to the ongoing opioid epidemic, which continues to devastate communities across the nation. They contend that the increased funding for prevention, treatment, and recovery programs is essential to save lives, support individuals in recovery, and strengthen the public health infrastructure. Furthermore, supporters highlight that the new policy mandates for insurance coverage and Medicaid payments will reduce barriers to life-saving treatments like MAT and opioid overdose reversal agents, ensuring more equitable access to care.
Opponents contend
Opponents may raise concerns about the sheer scale of federal spending proposed, arguing that it could contribute significantly to the national debt without sufficient oversight on effectiveness. Critics might also contend that the federal mandates on state Medicaid programs and private insurance plans represent an overreach into areas traditionally managed at the state or private sector level, potentially leading to unintended consequences or administrative burdens. Some may also question the allocation formulas, arguing they might not effectively target the most critical areas of need.
The bill is moderately complex due to its numerous amendments to existing statutes and detailed funding allocations, requiring a dedicated read to fully grasp its scope. The estimated reading time is appropriate for the bill's length and complexity.
Section 2(a)
Grants to Enhance Access to Substance Use Disorder Treatment
This provision authorizes and appropriates $4,000,000 annually for fiscal years 2027 through 2030 for grants under Section 3203 of the SUPPORT for Patients and Communities Act. These grants are intended to enhance access to substance use disorder treatment services.
Supporters argue
Supporters argue that sustained funding for substance use disorder treatment grants is crucial for expanding access to care, particularly in underserved areas, and for addressing the ongoing public health crisis.
Critics contend
No specific opposition is typically raised against direct funding for substance use disorder treatment, though some may question the efficiency or targeting of such grants.
Tradeoffs
The primary tension involves ensuring that grant funds are distributed equitably and effectively to areas with the greatest need, balancing broad access with targeted intervention.
Section 2(b)
Access to Increased Drug Disposal
This section authorizes and appropriates $10,000,000 annually for fiscal years 2027 through 2030 to carry out Chapter 2 of Subtitle B of Title III of the SUPPORT for Patients and Communities Act, which focuses on increasing access to drug disposal options. This funding aims to prevent misuse of unused prescription medications.
Section 3(a)
First Responder Training for Opioid Overdose
This provision authorizes and appropriates $77,000,000 annually for fiscal years 2027 through 2030 for first responder training programs under Section 546(h) of the Public Health Service Act. This funding supports training for first responders on how to recognize and respond to opioid overdoses, including the administration of overdose reversal medications.
Section 3(e)
Mental and Behavioral Health Education and Training Grants
This section authorizes and appropriates $75,000,000 annually for fiscal years 2027 through 2030 for mental and behavioral health education and training grants under Section 756(f) of the Public Health Service Act. These grants aim to increase the number of mental and behavioral health professionals, particularly in underserved areas, to address workforce shortages.
Section 3(q)
Preventing Overdoses of Controlled Substances
This provision authorizes and appropriates a substantial $516,000,000 annually for fiscal years 2027 through 2030 for programs under Section 392A(e) of the Public Health Service Act. This funding supports a wide range of activities aimed at preventing overdoses of controlled substances, including public awareness campaigns, prescriber education, and data collection.
Section 4(a)
Reauthorization and Improvement of Recovery Housing Program
This section reauthorizes the Recovery Housing Program, appropriating $60,000,000 annually for fiscal years 2027 through 2032. It amends the funding formula to prioritize states with the greatest need, based on unemployment rates (15%), labor force participation rates (15%), and age-adjusted rates of drug overdose deaths (70%). It also increases the requirement for states to expend funds from 30% within one year to 50% within two years.
Section 4(c)
Comprehensive Opioid Abuse Grant Program
This provision authorizes and appropriates $500,000,000 annually for fiscal years 2027 through 2030 for the Comprehensive Opioid Abuse Grant Program under the Omnibus Crime Control and Safe Streets Act of 1968. This program supports state and local efforts to combat opioid abuse through law enforcement, treatment, and prevention initiatives.
Section 5(a)(1)
State Opioid Response Grants
This provision authorizes and appropriates a substantial $5,500,000,000 annually for fiscal years 2027 through 2031 for State Opioid Response (SOR) Grants. It also adds flexibility, allowing states and Indian Tribes to use these funds for substance use disorder treatment and related services regardless of whether the patient has a primary diagnosis of opioid use disorder, as long as a SUD diagnosis exists. States can also allocate funds to local governments.
Section 5(a)(3)
Substance Abuse Prevention and Treatment Block Grants
This provision authorizes and appropriates $3,000,000,000 annually for fiscal years 2027 through 2031, and $2,500,000,000 annually for fiscal years 2032 through 2036, for the Substance Abuse Prevention and Treatment Block Grants. These block grants provide flexible funding to states for a wide range of substance abuse services.
Section 6
Eliminating Insurance Barriers to Medication-Assisted Treatment (MAT) in Medicaid
This section amends the Social Security Act to prohibit states from imposing any utilization control policies or procedures, including prior authorization requirements, for medical assistance for medication-assisted treatment (MAT) under Medicaid. This change takes effect on October 1, 2026, aiming to remove administrative hurdles that delay or deny access to MAT.
Section 7
Limitations on Cost-Sharing for Opioid Overdose Reversal Medications
This section mandates that group health plans, health insurance issuers, and Medicare Part D plans must provide coverage for at least one formulation of an opioid overdose reversal agent without imposing any cost-sharing requirements (deductibles, copayments, coinsurance) or utilization controls (like prior authorization). This applies to plan years beginning on or after January 1, 2027, and includes a safe harbor for high deductible health plans (HDHPs).
Section 8(a)
Loan Repayment Program for Substance Use Disorder Treatment Workforce
This section increases the annual appropriation for the Loan Repayment Program for the Substance Use Disorder Treatment Workforce to $65,000,000 for fiscal years 2027 through 2031. It also clarifies that payments made under this program on behalf of an individual shall not be considered taxable income under the Internal Revenue Code of 1986.
Section 9
Medicaid Payments for Behavioral Health and Mental Health Providers
This section mandates that, from October 1, 2026, to October 1, 2030, state Medicaid programs must pay physicians and applicable professionals for certain mental and behavioral health services (when provided for a substance use disorder diagnosis) at a rate not less than 100% of the Medicare Part B payment rate (or higher, if specified). It also provides 100% Federal Medical Assistance Percentage (FMAP) for the portion of state expenditures attributable to this increased payment rate, and disregards these enhanced payments from territorial limits.
Section 10
CMI Demonstration to Test Recovery Housing for Individuals with Opioid Use Disorder Under Medicaid
This section directs the Center for Medicare and Medicaid Innovation (CMI) to conduct a demonstration project to test providing Medicaid managed care entities with an elevated global capitated budget. This budget would allow states to provide medical assistance for recovery housing for eligible Medicaid beneficiaries (aged 21-65, OUD diagnosis, no permanent residence, receiving MAT or recently completed it) to see if it reduces emergency department visits, hospitalizations, and program expenditures or improves quality of care. The CMI must select at least two eligible states, prioritizing those with high per capita drug poisoning deaths and low physician reimbursement rates.
Section 11
Extension of Medicaid Delivery System Reform and Incentive Payment (DSRIP) Waivers
This section mandates that the Secretary of Health and Human Services extend certain existing Medicaid Section 1115 waivers (DSRIP waivers) to December 31, 2028, for states that were among the top 10 for highest per capita drug poisoning deaths in 2023-2025 and had a waiver in effect as of January 1, 2022. The extension will apply the same annual dollar allotment as the current waiver period and allow funds to support training for direct service workers providing home and community-based services.
Section 12
Expanding Drug-Free Communities Support Grants
This section amends the Drug-Free Communities Act to allow for subsequent additional grants and renewal grants to eligible coalitions, beyond the initial additional grant. It also introduces a priority for awarding these grants to eligible coalitions serving communities in states with high mortality rates relating to opioid use disorder. A recipient of a subsequent renewal grant may not receive further grants.
Section 13
Support for Law Enforcement Mental Health and Wellness
This section authorizes and appropriates $15,000,000 annually for fiscal years 2027 through 2030 for grants under the Omnibus Crime Control and Safe Streets Act of 1968. These grants are specifically for establishing peer mentoring mental health and wellness pilot programs within State, Tribal, and local law enforcement agencies.
Section 14
Adverse Childhood Experiences (ACEs) Response Team Grant Program
This section establishes a new grant program, authorizing $10,000,000 annually for fiscal years 2027 through 2030, for the Attorney General (in coordination with HHS) to make grants to states, local governments, Indian Tribes, and community-based organizations. Funds are to be used to establish ACEs response teams, including developing protocols for children exposed to trauma, referral partnerships with behavioral health providers, integrating services, providing trauma-informed care training, and supporting cross-system collaboration.
This section details the weighting of factors for prioritizing states for the Recovery Housing Program: 15% for highest average unemployment rates, 15% for lowest average labor force participation rates, and 70% for highest average age-adjusted rates of drug overdose deaths.
Section 4(a)(2)(B)
Why it matters:This is standard legislative practice for defining allocation formulas, but the specific weighting can have significant political and fiscal implications for different states.
Case for: Proponents argue that weighting drug overdose deaths at 70% ensures that the funds are primarily directed to the states experiencing the most severe impacts of the opioid crisis, while also acknowledging socio-economic factors that contribute to vulnerability.
Case against: Critics might argue that a 70% weighting for overdose deaths could disproportionately benefit certain states while potentially overlooking other states with significant, but perhaps less acute, needs or those with strong prevention programs that keep overdose rates lower. Some may also argue that economic factors should have a higher weighting.
Estimated impact: This formula will determine the allocation of $60,000,000 annually for six fiscal years (FY27-32) for the Recovery Housing Program, significantly impacting which states receive the most substantial support.
This subsection specifies that 15% of the remaining State Opioid Response Grant funds (after Indian Tribe set-aside) shall be made available to states with the highest mortality rate related to opioid use disorders. It also mandates that the Secretary develop a formula to avoid 'significant cliff' effects between states with similar mortality rates.
Section 5(b)(2)
Why it matters:This is a technical detail designed to ensure fairness and stability in funding, which is standard. However, the 'significant cliff' avoidance mechanism is a subtle but important policy choice.
Case for: Proponents argue that prioritizing states with the highest mortality rates ensures that the most severely impacted areas receive critical funding, while the 'cliff' avoidance mechanism prevents abrupt and disruptive changes in funding for states with similar needs.
Case against: Some states might argue that focusing solely on mortality rates, even with cliff avoidance, doesn't fully capture the burden of the opioid crisis, such as high rates of non-fatal overdoses or rising prevalence rates. The 'cliff' mechanism could also be seen as complex to implement.
Estimated impact: This provision directs 15% of the annual $5.5 billion in State Opioid Response Grants (after the tribal set-aside) to a specific subset of states, amounting to hundreds of millions of dollars annually, and influences the stability of funding for many states.
This section defines 'mental health and behavioral health services' for the purpose of Medicaid payment mandates. It includes specific evaluation and management services, counseling services, opioid use disorder treatment services under Section 1866F, and 'any other services the Secretary determines are necessary'.
Section 9(zz)(1)(A)
Why it matters:Defining terms in a dedicated subsection is standard, but the broad discretion given to the Secretary for 'any other services' could be seen as a way to allow for future expansion of covered services without further legislative action, or to avoid listing every specific service in the bill.
Case for: Proponents argue that a broad definition, coupled with Secretarial discretion, ensures that Medicaid can adapt to evolving clinical best practices and cover all necessary services for individuals with SUD, rather than being limited by a static list.
Case against: Critics might argue that granting such broad discretion to the Secretary could lead to unpredictable program expansion and costs for states, or that it bypasses congressional oversight on what constitutes covered services under a federal mandate.
Estimated impact: This definition directly impacts which services will be subject to the new Medicaid minimum payment rates and enhanced FMAP, potentially affecting billions of dollars in federal and state expenditures and significantly expanding access to a wider range of behavioral health services for Medicaid beneficiaries.